Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 13/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239723 | 1.00 | ALDH1A1 (0.40) | ALDH1A1NPC1ABCB1TDP1MAPK1 | |
| SCHEMBL18521396 | 0.82 | ALDH1A1 (0.44) | ALDH1A1NPC1ABCB1TDP1MAPK1 | |
| SCHEMBL27087661 | 0.81 | ALDH1A1 (0.45) | ALDH1A1NPC1ABCB1CHRNB2CHRNA5 | |
| SCHEMBL16576324 | 0.81 | ALDH1A1 (0.45) | ALDH1A1NPC1ABCB1CHRNB2CHRNA5 | |
| SCHEMBL20557502 | 0.81 | ALDH1A1 (0.45) | ALDH1A1NPC1ABCB1CHRNB2CHRNA5 | |
| SCHEMBL17976786 | 0.80 | ALDH1A1 (0.46) | ALDH1A1NPC1ABCB1 | |
| SCHEMBL18490597 | 0.80 | ALDH1A1 (0.46) | ALDH1A1NPC1TDP1MAPK1HIF1A | |
| SCHEMBL25997355 | 0.80 | ALDH1A1 (0.46) | ALDH1A1NPC1TDP1MAPK1HIF1A | |
| SCHEMBL21877952 | 0.80 | ALDH1A1 (0.46) | ALDH1A1NPC1TDP1MAPK1HIF1A | |
| SCHEMBL14615902 | 0.80 | ALDH1A1 (0.44) | ALDH1A1NPC1ABCB1SLC43A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ALDH1A1 277/4885NPC1 2305/4885ABCB1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.